J&J pill clears skin in two late-stage psoriasis studies

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down the inflammation involved in psoriasis and other immune diseases.

Incyte sinks on setback for drugs acquired in $750M buyout

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans.

Reducing variability in gene expression: bottlenecks and solutions

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless founded a new startup and Novartis licensed another radiopharma drug.

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy

The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne gene therapies despite questions about their effectiveness.